UCB has filed a patent for isolated antibody fragments, specifically knob domains of bovine ultralong CDR-H3, and their use in therapy. The patent also covers methods of preparing these fragments. GlobalData’s report on UCB gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on UCB, Human telomerase RT biomarker was a key innovation area identified from patents. UCB's grant share as of January 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
Antibody fragment from bovine ultralong cdr-h3 for therapy
The patent application (Publication Number: US20240024520A1) describes isolated antibody fragments that target specific antigens of interest, such as the component C5 of the Complement or human serum albumin. These antibody fragments are characterized by their unique structure, including the presence of cysteine residues, disulphide bonds, and specific amino acid motifs. The fragments can vary in length from 5 to 55 amino acids and may be fully bovine, chimeric, or synthetic. Additionally, the patent covers the fusion of these antibody fragments with effector molecules, such as albumin or proteins with albumin binding domains, for enhanced therapeutic applications.
Furthermore, the patent application details the production and use of these antibody fragments, including the creation of phage display libraries containing ultralong CDR-H3 sequences from bovine immunizations. Methods for generating these libraries, enriching them against specific antigens, and sequencing the isolated antibody fragments are outlined. The application also includes the production of pharmaceutical compositions containing the antibody fragments, as well as the use of polynucleotides, vectors, and host cells for their expression. Overall, the patent application provides a comprehensive overview of the development, production, and application of novel antibody fragments with potential therapeutic benefits for various medical conditions.
To know more about GlobalData’s detailed insights on UCB, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
